Investigation Report on China Tropisetron Market, 2010-2019
Cancer patients are afraid of such adverse reactions as nausea and emesis caused by chemotherapy. Severe nausea and vomiting will make future chemotherapy a daunting experience for patients. They may even feel unwilling or give up further chemotherapy, which will make chemotherapy difficult to continue. 5-HT3 receptor antagonist, an antiemetic, acts by competitively preventing 5-HT from combining with 5-HT3 receptor. Ever since GSK developed the first generation of selective 5-HT3 receptor antagonist ondansetron under the trade name of Zofran, a bunch of derivatives have come out, including tropisetron made by Novartis under the trade name of Navoban.
Tropisetron, developed by Novartis, entered the market in the Netherlands in 1992 and then the Chinese market in the late 1990s. Tropisetron got administrative protection authorized by the Chinese government in Mar. 1994 after its original developer Sandoz submitted application. But it is now a generic drug for its patent expired on Sep. 22, 2001. Tropisetron develops fast into the absolute leader antiemetics after entering China with annual sales rising from CNY 41 million in 2005 to CNY 600 million in 2014 and CAGR reaching up to 34.7% during the period of 2005-2014. Currently, the tropisetron market in China is basically occupied by generic drugs which come from the following companies: Southwest Pharamceutical Co., Ltd, Wellso Pharmaceutical Co., Ltd, ReYoung Pharmaceutical Co., Ltd, Shandong Luoxin Pharmacy Stock Co., Ltd and Qilu Pharmaceutical Co., Ltd
Tropisetron has big profit margins and is easy to be applied to clinics. Since there are hundreds of thousands of cancer patients undergoing chemoradiotherapy, tropisetron enjoys a promising market in China.
Readers can get at least the following information through this report:
market share of manufacturers of tropisetron in Chinese market
price of tropisetron in Chinese market
major manufacturers of tropisetron in China
share of different dosage forms of tropisetron in Chinese market
market outlook of tropisetron in China
The author suggests the following groups of people purchase this report:
investors/ research institutions interested in Chinese medicine market
any interest in Chinese medicine market, please contact CRI for customized survey service
Please Note: All reports from China Research and Intelligence are written in Chinese, then translated to English. This process takes approximately 5 business days from the date the order is placed